BOULDER, Colo., April 25, 2017 /PRNewswire/ -- i2 Pharmaceuticals, Inc., a biopharmaceutical company focused on next generation
Dr. Eaton stated, "We are extremely pleased to welcome Mark as CBO to i2's senior management team. Mark is joining us as we enter a strategic growth-phase and will be instrumental in driving our new business opportunities in antibody therapeutics. With twenty plus years of impressive business development experience and accomplishments in the antibody and empowered antibody space he will help us craft the next generation in antibody therapeutics."
"I am excited for this opportunity and look forward to working with the i2 team as we seek to optimize the value of the Company's unique and proprietary suite of transformative technologies and assets. The breadth of i2's cutting edge discovery technologies allows me to utilize my antibody experience as well as the chance to forge new collaborations outside this space as well," Mr. Kubik added.
Mark has extensive experience in the biopharmaceutical industry as a business development executive in roles of increasing impact in bioscience and drug discovery and development. He has led negotiation of transformative and award-winning technology and product partnerships for leading therapeutics companies including global co-development agreements on behalf of Abgenix (now Amgen) with Immunex for Vectibix® (panitumab), on behalf of Seattle Genetics with Takeda for Adcetris® (brentuximab vedotin) and on behalf of MacroGenics with Gilead. Mark graduated cum laude from the University of Colorado-Boulder (CU) in Molecular, Cellular and Developmental Biology (MCDB) and also holds an MBA in Finance from CU.
About i2 Pharmaceuticalsi2 Pharmaceuticals is a biopharmaceutical company focused on next generation discovery and development of therapeutics with a focus on personalized cancer treatment. i2 is unique in that it generates its pipeline of product candidates from its proprietary suite of transformative technologies including small molecules, antibodies and nucleic acid based therapeutics. We are innovators coupling the power of cutting edge discovery technologies with ground breaking diagnostics to accelerate the development of more effective, safer therapeutics. For more information please visit http://www.i2pharma.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/i2-pharmaceuticals-appoints-chief-business-officer-300445633.html
SOURCE i2 Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All